Search
The ‘i4MDS’ consortium looks to the future at its second general meeting
The International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—also known as ‘i4MDS’—held its second general meeting in The Hague from February 9–10, 2024.
Read more‘i4MDS’ consortium wins prestigious EHA Innovation Grant
In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.
Read moreImmune Therapies for Hematologic Disorders
Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.
Read moreMesenchymal Stromal Cells (MSC)
The focus of the current MSC Specialized Working Group is to better understand mechanisms through which MSCs could modulate immune responses, identify individual cells belonging to the innate and adaptive immune responses that interact with MSCs and define the molecular…
Read moreEHA-KCS Hematology Tutorial
EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.
Read moreLa Cantera coaching
Disease-orientated training courses for young clinicians and researchers, inspired by a world-renowned football academy model. Call for interest from SWGs
In 2025, EHA will fund an additional course based on the La Cantera model.